Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred a rapid correction, marking the first material correction of the current bull market. However, this doesn’t mean the bears have been vindicated, so says Wells
TipRanks · 1d ago
Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 102% In The Last Three Years
Global Blood Therapeutics, Inc. (NASDAQ:GBT) shareholders might be concerned after seeing the share price drop 19% in...
Simply Wall St. · 2d ago
Hedge Funds Have Never Been This Bullish On Global Blood Therapeutics Inc (GBT)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 4d ago
Wall Street’s top analysts are recommending stocks like Uber and Lovesac amid market volatility
CNBC used TipRanks analyst ranking service to pinpoint Wall Street's best-performing stocks, like Uber and Lovesac. · 6d ago
Global Blood Therapeutics (GBT) Investor Presentation - Slideshow
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:39
GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D. Discussion to Focus on SCD Treatment Progress and Management During COVID-19 Pandemic SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT)
GlobeNewswire · 09/09 13:00
Global Blood Therapeutics inks distribution pact with Biopharma-MEA for SCD med
Global Blood Therapeutics (GBT) +1.5% AH, has entered into an exclusive agreement with Biopharma-Middle East and Africa (Biopharma-MEA) for the distribution of Oxbryta (voxelotor) tablets in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.Oxbryta is a once-daily, oral therapy
Seekingalpha · 09/08 20:51
GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries
More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab EmiratesSOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it has entered
GlobeNewswire · 09/08 20:05
Why Is Global Blood (GBT) Down 5.6% Since Last Earnings Report?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/04 16:31
Benzinga's Top Upgrades, Downgrades For August 25, 2020
Upgrades * According to Telsey Advisory Group, the prior rating for Burlington Stores Inc (NYSE: BURL) was changed from Market Perform to Outperform. In the first quarter, Burlington Stores showed an EPS of $4.76, compared to $1.26 from the year-ago quarter. At the moment, the stock has a 52-week-high
Benzinga · 08/25 14:35
Global Blood Therapeutics shares are trading higher after Raymond James initiated coverage on the company's stock with an Outperform rating and announced a $115 price target.
Benzinga · 08/25 13:22
Global Blood Therapeutics initiated at outperform with $56 price target at Raymond James
GBT | Complete Global Blood Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. · 08/25 12:16
Raymond James Initiates Coverage On Global Blood Therapeutics with Outperform Rating, Announces Price Target of $115
Raymond James analyst Danielle Brill initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Outperform rating and announces Price Target of $115.
Benzinga · 08/25 10:50
Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms
Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era".It is evident in both the data and my personal experience that Oxbryta is being welcomed by patients and hematologists, alike, with open arms.Entry into the younger market and full approval is sure to accelerate revenues. I find this outcome to be likely.Stock in Global Blood Therapeutics has yet to realize the full potential of Oxbryta. Investors still have time to join in this story and reap rewards.
Seekingalpha · 08/20 15:44
Global Blood Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 08/07 15:02
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees options to purchase an
GlobeNewswire · 08/07 12:00
Global Blood files for $200M mixed shelf
Global Blood Therapeutics (GBT -5.3%) has filed a prospectus for a $200M mixed shelf offering.
seekingalpha · 08/07 00:13
Global Blood Therapeutics EPS beats by $0.29, beats on revenue
Global Blood Therapeutics (NASDAQ:GBT): Q2 GAAP EPS of -$0.86 beats by $0.29. Revenue of $31.5M beats by $12.37M. Shares +7.51%. Press Release
seekingalpha · 08/06 01:15
Global Blood Therapeutics (GBT) Reports Q2 Loss, Tops Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of 27.12% and 67.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 21:35
GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results
Achieved Oxbryta® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions     Announced plans to seek approval of Oxbryta for younger pediatric patients in the United States and seek approval of Oxbryta in Europe   Con
GlobeNewswire · 08/05 20:01